Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 4, Issue 1-2, Pages 7-10
http://dx.doi.org/10.1155/S1357714X00000025

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy

1Department of Oncology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
2Department of The National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Departments of Pathology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
4Departments of Radiology, The Tel-Aviv Sourasky Medical Center, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Copyright © 2000 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident.

Results. The true objective response rate was 0%. However, disease stabilization and clinical benefit response were observed in five patients (70%) for 13–96 weeks.

Discussion. Postponing the inevitable death with a relatively non-toxic treatment, is, in our opinion, an important issue especially in young patients.Thus it may be justified and warranted to investigate the activity of gemcitabine in a larger group of patients with bone sarcomas.